GS-1101: A delta-specific PI3K inhibitor in chronic lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 8, Issue 1, 2013, Pages 22-27

  MacIas Perez, Ines M ^a   Flinn, Ian W ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

B cell receptor; BCR; CAL 101, GS 1101; Chronic lymphocytic leukemia; CLL; Microenvironment; New targets; PI3 Kinase; PI3K; PI3K delta; Signaling pathways

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD20 ANTIBODY; FLUDARABINE; IDELALISIB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; RITUXIMAB; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; SIDE EFFECT; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; PURINES; QUINAZOLINONES;

EID: 84874227843     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0142-1     Document Type: Article

References (52)

1. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
3. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br J Haematol. 2007;139:809.
4. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47:1477.
5. Goldin LR, Slager SL, Familial CLL. Genes and environment. Hematology Am Soc Hematol Educ Program. 2007;339.
6. Kipps TJ. Chronic Lymphocytic Leukemia and Related Diseases. Williams Hematology. New York: McGraw-Hill Professional; 2010. p. 1431-82.
7. Wierda WG, Keating MJ, O'Brien S. Chronic lymphocytic leukemias. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles & Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 2278-92.
8. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/ results?term=CLL&recr=Open&rslt=&type=Intr&cond=&intr= &outc=&spons=&lead=&id=&state1=&cntry1=&state2= &cntry2=&state3=&cntry3=&locn=&gndr=&rcv-s=&rcv-e= &lup-s=&lup-e =.
9. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37-50.
10. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1994;94:1840-7.
11. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-54.
12. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. NEJM. 2003;348:1764-75.
13. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEJM. 2000;343:1910-6.
14. •• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. NEJM. 2011;356:2497-506. Identified nine genes with significant mutation frequencies, four of which had been previously described and five of which had no established role in CLL. These newly identified patterns of genetic lesions provide further insight into CLL pathogenesis and potential therapeutic targets.
15. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367-75.
16. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-64.
17. • Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurse-like cell co-cultures and after BCR stimulation. Blood. 2009;13(13):3050-8. These data demonstrate CLL cells upregulate expression of CCL3 in response to the microenvironment.
18. •• Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-74. These data show for the first time direct evidence of BCR activation in CLL lymph nodes as a form of tumor microenvironment interactions in vivo.
19. •• Minden MD, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonmous signaling. Nature. 2012; Epub ahead of print. Evidence CLL-derived BCRs are autonomously activated in the absence of external antigens and identified an intrinsic motif required for autonomous BCR signaling. Establishes a framework for CLL therapy based on targeting autonomous BCR activation.
20. Chiorazzi N, Rai KR, Ferrarini M. Chronic Lymphocytic Leukemia. NEJM. 2005;352:804-15.
21. • Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NFκB activation and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563-74. Gene expression profiling identified pathways activated in CLL cells in the tissue microenvironment that sustains CLL proliferation and survival in vivo. These data provide the framework for new compounds to block these essential pathways in CLL.
22. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10:342-52.
23. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329-41.
24. Cantrell DA. Phosphoinositide 3-kinase signaling pathways. J Cell Sci. 2001;114:1439-45.
25. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancer. Science. 2004;304:554.
26. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274:10963-8.
27. Bi L, Okabe I, Bernard DJ, et al. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI3-kinase. Mamm Genome. 2002;13:169-72.
28. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110d PI3-kinase mutant mice. Science. 2002;297:1031-4.
29. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-coupled phosphoinositide 3-kinase g in inflammation. Science. 2000;287:1049-53.
30. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110d in signaling by the B-cell receptor complex. Mol Cell Biol. 2002;22:8580-91.
31. Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196:753-63.
32. Kang S, Denley A, Vanhaesebroeck B, et al. Oncogenic Transformation induced by p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase. PNAS. 2006;103:1289-94.
33. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3 K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100:3741-8.
34. Brunn GJ, Williams J, Sabers C, et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256-67.
35. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007;404:15-21.
36. Garcia-Echeverria C, Sellers WR. Drug Discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511-26.
37. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20:87-90.
38. Workman P, Clarke PA, Raynaud FI, et al. Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. Cancer Res. 2010;70:2146-57.
39. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. PNAS. 1997;94:4330-5.
40. •• Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110 delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591-4. Identified GS-1101 as a potent and selective PI3K δ inhibitor in a kinome-wide screen and showed it to induce apoptosis and reduce Akt activation in multiple B-cell malignancies.
41. •• Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078-88. Establishes the clinical rationale for developing GS-1101 as a first-in-class targeted therapy in CLL.
42. Burger JA. Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia. Curr Hematol Rep. 2012;7:26-33.
43. Ghia P, Chiorazzi N, Stamatopoulos K, et al. Microenvironmental influences in chronic lymphocytic leukemia: the role of antigen stimulation. J Intern Med. 2008;264:549-62.
44. •• Hollenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603-12. These correlative studies provide an explanation to the clinical activity of GS-1101 in CLL patients who typically experience a rapid reduction in lymphadenopathy/organomegaly with a transient surge in lymphocytosis at the start of therapy.
45. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2.
46. • Flinn IW, Byrd JC, Furman RR, Brown JR, Benson DM, Coutre SE, et al. Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110{Delta} Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. ASH Annu Meet Abstr. 2009;114(22):922. This is the first clinical results of GS-1101 in patients and presents activity and toxicity of the molecule across various hematologic malignancies.
47. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-85.
48. •• Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, et al. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annu Meet Abstr. 2011;118(21):1787. It is interesting to contrast the activity of single agent GS-1101 with combination therapies with GS-1101, especially the differences in the absolute lymphocye count and nodal masses.
49. Webb HK, Chen H, Yu AS, Peterman S, Holes L, Lannutti B, et al. Clinical Pharmacokinetics of CAL-101, a p110{delta} Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies. ASH Annu Meet Abstr. 2010;116(21):1774.
50. •• Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(suppl: abstr 6631). This presentation outlines the activity and toxicity of GS-1101, specifically in CLL patients.
51. Kahl B, Byrd J, Flinn I, Wagner-Johnston N, Spurgeon S, Benson D, et al. Significant Clinical Activity of CAL-101, An Isoformselective Inhibitor of Phosphatidylinositol 2 Kinase P110 delta, in Patients with Relapse or Refractory Indolent and Mantel Cell Lymphoma. ICML. 2011;abstr 350.
52. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in Fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;7(94):2033-9.